Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 78.50 - 116.83
Open     -
Vol / Avg. 0.00/11.64M
Mkt cap 164.99B
P/E 12.75
Div/yield 0.43/1.53
EPS 8.80
Shares 1.47B
Beta 0.80
Inst. own 86%
Jul 21, 2015
Q2 2015 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EDT - Add to calendar
Jun 9, 2015
Gilead Sciences Inc at William Blair Annual Growth Stock Conference - 10:30AM EDT - Add to calendar
May 28, 2015
Gilead Sciences Inc at Sanford C Bernstein Strategic Decisions Conference
May 19, 2015
Gilead Sciences Inc at UBS Global Healthcare Conference
May 13, 2015
Gilead Sciences Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Gilead Sciences Inc Annual Shareholders Meeting
Apr 30, 2015
Q1 2015 Gilead Sciences Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Gilead Sciences Inc Earnings Release
Mar 11, 2015
Gilead Sciences Inc at Barclays Healthcare Conference
Mar 3, 2015
Gilead Sciences Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 57.05% 48.45%
Operating margin 70.73% 61.33%
EBITD margin - 65.55%
Return on average assets 47.61% 42.13%
Return on average equity 106.60% 90.32%
Employees 7,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection, oncology or inflammation and serious cardiovascular and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company’s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. Sales of the Company’s antiviral products, which include products in the Company’s HIV and liver diseases areas described above, were $9.34 billion in 2013. This represented 83% of the Company’s total revenues in 2013.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul R. Carter Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
Taiyin Yang Ph.D. Executive Vice President - Pharmaceutical Development and Manufacturing
Age: 60
Bio & Compensation  - Reuters
John F. Cogan Jr., P Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 82
Bio & Compensation  - Reuters